Cancer metastasis accounts for a significant proportion of morbidity and mortality in patients. Effective means of treating disseminated disease remains elusive. The purpose of this study was to determine whether genetically modified endothelial cells ( GMEC ) can selectively target and deliver recombinant therapeutic molecules to sites of tumor metastases. Following the establishment of lung metastases of 4T1 mammary tumor in mice, intravenously ( i.v. ) administered, lacZ transgene -expressing endothelial cells ( lacZ -GMEC ) accumulated at the tumor sites. An average of 32% and 90% of the pulmonary metastases were X -gal stained following one and three tail vein injections of 10 5 lacZ -GMEC, respectively. The linear pattern of X -gal staining seen within the tumor sites and the histological appearance of the tumor vasculature were consistent with the incorporation of lacZ -GMEC into blood vessels. In C57Bl / 6 mice harboring lung metastases of melanoma, the administration of three sequential i.v. injections of 10 5 endothelial cells expressing a human interleukin 2 transgene abrogated the tumor metastases and prolonged survival of the animals. These results demonstrate that i.v. -administered GMEC can selectively accumulate, survive, and stably express exogenous genes at multiple tumor sites. These findings support a role for i.v. -administered GMEC as a potential therapeutic strategy for the systemic treatment of cancer metastases. Cancer Gene Therapy ( 2001 ) 8, 636 -648
A lthough there have been substantial advances in early detection and treatment of human cancers, survival for patients with certain forms of cancer has not improved. 1 -3 The prognosis for advanced solid epithelial tumors remains dismal, in part due to the occurrence of metastatic disease in many patients at the time of diagnosis, 3, 4 and the ineffectiveness of currently available methods to treat metastatic disease. Consequently, morbidity and/ or mortality remain high in this subset of patients, and novel treatment strategies are needed.
The growth and metastasis of tumors are dependent on the formation of neo-vessels that arise in response to angiogenic factors elaborated by tumor cells themselves. 5 -10 In previous reports, we and others have shown that the process of angiogenesis can be exploited to deliver recombinant molecules to the sites of newly forming blood vessels by using genetically modified endothelial cells ( GMEC ). In particular, when lacZ genetransduced endothelial cells (lacZ -GMEC ) were injected intravenously, they migrated into and preferentially accumulated at sites of active angiogenesis induced by fibroblast growth factor (aFGF )-secreting NIH 3T3 cells. 11 Also, locally injected lacZ -GMEC can integrate into blood vessels formed in response to ischemia 12 or brain tumors. 13, 14 These findings suggest that physiologically driven or tumor-initiated angiogenesis could be used to promote the delivery of recombinant molecules to the angiogenic sites.
The delivery of therapeutic molecules that would interfere with tumor growth and metastases or their vascular supply may now be feasible using implants of genetically modified cells. 14 -17 Endothelial cells are excellent vehicles for drug delivery because of their ability to express a wide variety of endogenous 18 and exogenous genes, 17,19 -21 and their strategic location within the vascular compartment. Initially, we and others found that injection of cytokine 22 or prodrug gene -expressing 20 endothelial cells directly into tumor sites resulted in significant antitumor effects. Because sites of metastases are areas of active angiogenesis, 23, 24 and i.v.-injected GMEC can selectively become incorporated into these sites, 11 we decided to investigate whether systemic administration of GMEC may be a useful approach for targeting recombinant therapeutic molecules to metastatic sites throughout the body. To determine the feasibility of an endothelial cell -based systemic gene therapy for metastatic cancer, we investigated the efficiency of multifocal tumor targeting by i.v. -administered, lacZ -GMEC, and the therapeutic potential of i.v.-injected, recombinant human interleukin 2 (rhIL -2 ) transgene -expressing endothelial cells in a murine experimental metastasis model. Our studies demonstrate efficient targeting and eradication of tumor metastases by the systemic administration of GMEC.
MATERIALS AND METHODS

Animals
Female BALB /c and C57Bl/ 6 mice, 6 -8 weeks of age, were purchased from the National Cancer Institute Animal Program ( Frederick, MD ) and used for this study. Protocols for husbandry and experimental manipulation were approved by the Georgetown University Animal Care and Use Committee. All mice were housed in a pathogen-free environment, and National Institutes of Health -Centers for Disease Control biosafety level 2 containment procedures were observed. Experiments to determine the efficiency of GMEC targeting of multiple tumor sites were conducted on female BALB /c mice whereas a C57Bl/ 6 mouse model was used to evaluate the ability of cytokine gene -modified endothelial cells to target multiple tumor sites and induce tumor regression. The different strains of mice were used for the respective studies to ensure that the mice were syngeneic for both tumor cell lines and endothelial cells, thereby avoiding the immunological rejection of either tumor cell implants or the gene -modified endothelial cells.
Endothelial cell isolation
Mouse microvascular endothelial cells (MECs) were isolated from the lungs of BALB /c and C57Bl /6 mice using a multistep method as previously reported. 19 Briefly, lungs were removed from the animals and minced into 1 -2-mm pieces, washed, and digested with collagenase (Worthington Biochemical, Freehold, NJ; 2 mg /mL in phosphate -buffered saline [PBS ]), for 20 minutes at 378C in a shaker water bath at 80 cycles /min. Subsequently, the products of digestion were transferred to a sterile 50 - 7.4 ) and allowed to pellet at unit gravity for 30 minutes at 48C. The supernatant was passed through a 110-m pore size nylon screen (Nitex, Tetko, Elmsford, NY ) to remove the large fragments. The filtrate was passed through a 20 -m pore size nylon screen that was washed three times with isolation medium. Capillary and tissue fragments retained on the 20-m screen were collected, then washed with Ca 2 + -and Mg 2 + -free Hanks balanced salt solutions (CMF -HBSS ), pH 7.4, and suspended in 14 mL of CMF -HBSS buffered with 0.35 g NaHCO 3 /L and supplemented with 0.25% BSA and 25 mg STI / L, pH 7.4. Subsequently, the cell suspension was thoroughly mixed with 21 mL iso -osmotic Percoll with 10Â CMF -HBSS and centrifuged in a fixed angled rotor (JA -20, Beckman, Fullerton, CA ) at 20.000Âg for 60 minutes at 48C. Tufts of capillary endothelial cells from the third -to the tenth-milliliter fractions from the top of the gradient ( density, 1.006 -1.050 g/mL ) were collected, washed, and seeded on fibronectin -coated dishes containing endothelial cell growth medium ( M-199 with 20% fetal calf serum, 2 mM glutamine, 50 -100 g /mL endothelial cell growth supplement, and 50 U /mL heparin ). After a 72 -hour incubation period in a humidified incubator of 95% air and 5% CO 2 maintained at 378C, the contaminating nonendothelial cells were removed by labeling the cells with DiI-acetylated low -density lipoprotein ( DiI -Ac -LDL, Biomedical Technologies, Stoughton, MA ) and sorting with the fluorescence -activated cell sorter ( FACS ) as described by Voyta et al. 25 Endothelial cells obtained were examined for maintenance of differentiated endothelial cell makers, including cobblestone morphology and expression of acetylated low -density lipoprotein ( Ac -LDL ) receptor 25 and von Willebrand factor. 26 Confluent monolayer of the cells was examined under low power of a phase -contrast microscope for cobblestone morphology. Cells evaluated for expression of Ac -LDL receptor were cultured to semiconfluence. Thereafter, the cells were incubated with 10 g /mL of Dil -Ac -LDL ( Biomedical Technologies ) in endothelial cell growth medium for 4 hours at 378C. At the end of the incubation period, culture medium was removed and the cells were washed twice with probe -free medium for 5 minutes. The cells were examined with standard rhodamine excitation / emission filters. More than 95% of the sorted cells retained these differentiated endothelial cell makers. Endothelial cells at passages 3 or 4 were used for retroviral transduction.
Construction of retroviral vectors containing lacZ gene or rhIL -2 gene and transduction of endothelial cells
Retroviral vectors containing lacZ or rhIL -2 gene were constructed as previously reported. 11, 19 Culture supernatants containing infectious IL -2 -containing retroviral particles are produced by introducing the retroviral vector plasmids into the PA317 amphotropic packaging cell line. 27 To generate lacZ gene -modified endothelial cells (lacZ -GMEC ), the viral supernatant from the packaging cell line was used to transduce murine MECs that were isolated from the lungs of BALB/ c mice. Twenty four hours before infection, MECs at passage 3 or 4 were seeded onto fibronectin -coated 100 -mm plastic dishes at a 1:2 -1:3 split ratio. Following overnight culture of the cells, the medium was replaced with 5 mL of amphotropic viral stock with a titer of 5Â10 5 colony -forming units per milliliter titer and containing either the lacZ gene vector construct (LZSN ) or the parent vector with the neomycin resistance ( neo R ) gene alone (LXSN ) and 8 g /mL of polybrene. After 2 -4 hours incubation of the cells with the viral medium, 5 mL of virus -free, endothelial cell growth medium containing 8 g /mL of polybrene was added to each dish and incubated overnight at 378C. Thereafter, the cells were cultured in endothelial cell growth medium without polybrene. At confluence, the cells were sorted using FDG -FACS. Following two sequential cell sorts, more than 95% of the lacZ -GMEC expressed the product of lacZ gene, -galactosidase, as demonstrated by 4 -Cl -5 -Br-3-indolyl --D -galactopyranoside (X -Gal ) staining. Both lacZ -GMEC and neo R gene-expressing endothelial cells (neo -GMEC) retained the endothelial cell phenotype, including cobblestone morphology, uptake of Ac -LDL, 25 and expression of von Willebrand factor. 26 No replication-competent helper OJEIFO, LEE, REZZA, ET AL: ENDOTHELIAL CELL-BASED GENE THERAPY virus was detected in the culture medium of lacZ -GMEC or neo -GMEC during 25 passages of these cells.
To generate rhIL -2-GMEC, MECs were harvested from lungs of C57Bl /6 mice and transduced with retroviral vector containing hIL -2 gene under the transcriptional control of cytomegalovirus promoter as previously reported. 19 Briefly, helper -free culture supernatant from PA317 amphotropic packaging cell clones producing $10 6 G418 -resistant colony -forming units per milliliter was used to infect the endothelial cells. Twenty four hours before infection, MECs at passage 3 or 4 were seeded onto fibronectin -coated 100-mm plastic dishes at a 1:2 -1:3 split ratio. Following overnight culture of the cells, the medium was replaced with 5 mL of amphotropic viral stock containing either the rhIL -2 gene ( LNCIL -2 construct 19 ) or the parent vector with only the neo R gene ( LNCX construct ) and 8 g/mL polybrene to promote viral attachment to cells. The dishes were returned to the incubator and an additional 5 mL of fresh endothelial cell growth medium was added after 2 -4 hours. Subsequently, the dishes were incubated overnight and then refed with complete growth medium. Colonies were isolated by selection in 100 g /mL G418, the minimum concentration of G418 that was required to kill all cultured endothelial cells ( data not shown). After selection in G418, cell populations were expanded and characterized for rhIL -2 production as well as maintenance of endothelial cell phenotype. Recombinant hIL -2 secretion in vitro by the rhIL -2 -GMEC was assayed from 24 -hour culture supernatant of the cells.
The lacZ -, rhIL -2 -, and neo gene -expressing endothelial cells ( lacZ -GMEC, rhIL -2 -GMEC, and neo -GMEC, respectively ) retained the endothelial cell phenotype, including cobblestone morphology, uptake of Ac -LDL, and expression of von Willebrand factor. Again, no replication-competent helper virus was detected in the media of 25 passages in each of the gene-modified endothelial cells.
Quantitation of secreted rhIL -2 in culture media rhIL -2 protein secreted by cytokine gene -transduced and nontransduced endothelial cells were assayed in the culture media of the cells by enzyme -linked immunoabsorbance assay ( ELISA; Quantikine RD Systems, Minneapolis, MN ), following the manufacturer's instructions. The range of sensitivity of the ELISA assays was 30-2000 pg/ mL for IL-2. Functional IL -2 activity was determined by a microtiter colorimetric assay using the tetrazolium salt, 2,3 -bis( 2 -methoxy -4-nitro -5 -sulfophenyl ) -5 -[( phenylaminocarbonyl ]-2H -tetrazolium hydroxide ( XTT ), which is cleaved in mitochondria to a dark -blue formazan product, 28 to measure the proliferation of HT-2 cells ( ATCC, Rockville, MD ) in response to the cytokine. 29 Recombinant hIL -2 secretion in vitro by the rhIL -2-GMEC ranged from 28 to 78 ng /10 6 cells per 24 hours ( i.e., 368-1000 IU / 10 6 cells per 24 hours ) ( Table 1 ) . cells/ mL. More than 98% of the cells in suspension were singlets and more than 90% were viable based on their ability to exclude trypan blue.
In vivo tumor models Establishment of pulmonary metastases and administration of lacZ -GMEC. To determine the efficiency of multifocal tumor targeting by i.v.-administered lacZ -GMEC, a metastatic murine mammary tumor cell line, 4T1, was implanted in syngeneic BALB /c mice. The primary tumors were established by injecting 1Â10 5 4T1 cells suspended in 0.1 mL PBS into the first right thoracic mammary fat pad (MFP ) of the mice. Ten days after inoculation of 4T1 cells, when pulmonary metastases were first observed, mice were injected with lacZ -GMEC via the tail vein. Control groups included 4T1 tumor-bearing mice without GMEC or injected with 10 5 neo -GMEC, and non-tumor-bearing mice with or without lacZ -GMEC treatment. Tumor-bearing animals that received lacZ -GMEC were injected with either 10 5 , 10 6 , or 10 7 lacZ -GMEC via the lateral tail vein. At intervals of 4, 7, and 14 days after i.v. GMEC administration, animals in each group were sacrificed to follow the fate of injected cells over time. The primary tumor, skin, lungs, liver, spleen, bones, brain, and heart were removed and processed for histology and -galactosidase histochemistry to visualize the lacZ -expressing endothelial cells.
To determine the effect of multiple inoculations of relatively small doses of GMEC on the efficiency of tumor targeting, mice bearing 4TI lung metastases were given three sequential tail vein injections of 10 5 lacZ -GMEC. In this set of experiments, 2 weeks following the inoculation of 4T1 cells into the MFP, when many pulmonary metastases are 1 -2 mm in diameter, i.e., a point at which they begin to acquire a new blood supply, 24 the primary tumors were excised and mice were randomized into three groups. One group of mice was given three sequential tail vein injections of 10 5 lacZ -GMEC in 0.1 mL PBS. The second group received three sequential tail vein injections of 10 5 neo -GMEC in 0.1 mL PBS, and the third group was given three sequential tail vein injections of 0.1 mL PBS without GMEC. Administration of the GMEC was started on the third day following surgical excision of the primary tumor, and the injections were spaced 3 days apart. Three groups of non -tumor-bearing mice were also studied. These consisted of non -tumor-bearing mice given three sequential tail vein injections of 10 5 lacZ -GMEC or neo-GMEC, and non-tumor-bearing mice without GMEC. At weekly intervals, mice from each group were sacrificed to follow the fate of injected cells over time. Various tissues were excised from the animals and processed for histology and -galactosidase histochemistry as described below.
rhIL-2 -GMEC administration to mice bearing B16F10 melanoma pulmonary metastases. We employed an experimental metastasis model to evaluate the therapeutic potential of endothelial cell -based gene therapy approach for metastatic cancer. Pulmonary metastases were established by tail vein injection of 1Â10 5 B16F10 melanoma cells into C57Bl /6 mice. Seven to ten days following injection ( when lung tumors ranged from 0.5 -2 mm in diameter ), the mice were given the first of three intravenous injections of 1Â10 5 mouse MECs expressing rhIL -2 ( rhIL -2 -GMEC ), spaced 3 days apart. In vitro IL-2 secretion by rhIL -2 -GMEC ranged from 28 to 78 ng/10 6 cells per 24 hours, i.e., 368 to 1000 IU /10 6 cells per 24 hours ( Table 1 ). The control groups consisted of (1 ) mice that received the tumor cells and three injections of neo-GMEC, (2 ) mice that received the tumor cells alone, (3 ) mice that received three injections of rhIL -2 -GMEC alone, and ( 4) mice that received neither tumor cells nor GMEC. Purified rhIL -2 protein was not administered to animals in these studies because toxic doses of rhIL -2 would have been required to attain the serum levels of 2.8 -7.8 ng ( 36.8 -100 IU ) of rhIL -2 that would be comparable to the levels produced by the rhIL -2-GMEC at tumor sites. 30, 31 After GMEC administration, the animals were monitored for survival. Lungs of mice that died or were sacrificed when they became ill were removed and examined for number and size of pulmonary metastases. Otherwise, groups of mice were sacrificed at periodic intervals after the administration of the GMEC and their lungs examined to follow the rate of regression of the lung metastases.
Tissue fixation, X -gal and CD31 immunohistochemical staining
Various tissues, including lungs, brain, liver, spleen, bone, skin, and heart harvested from individual animals were processed separately for -galactosidase histochemistry and histology. The organs were first washed in PBS, pH 7.4, and then fixed in a solution of PBS containing 2% ( vol /vol ) formaldehyde and 0.2% ( vol /vol ) glutaraldehyde for 60 minutes. After fixation, tissues were rinsed three times in PBS and incubated for 24 hours at 48C in X -gal staining solution (X -gal 1 mg /mL; 5 mM potassium ferricyanide; 5 mM potassium ferrocyanide; 2 mM MgCl 2 ; 0.02% [vol / vol ] Nonidet P -40; 0.01% [ wt /vol ] sodium deoxycholate in PBS ). At the end of the incubation period, organs were rinsed with 3% dimethyl sulfoxide in PBS followed by PBS alone. The organs were then visualized and photographed using an Olympus SZH stereo microscope. Subsequently, X -gal -stained tissues were fixed further at 48C for 2 hours in 2% paraformaldehyde in 0.1 M PBS, pH 7.4, followed by rinsing in 0.1 M PBS and dehydration in 3% sucrose in 0.1 M PBS before performing cryosections.
In addition to -galactosidase histochemistry, CD31 immunohistochemical staining of the excised tissues was performed by means of a double antibody -labeling method. X -gal -stained tissues were fixed in neutral buffer containing 3.7% formalin for > 24 hours, processed, and embedded in paraffin. The paraffin tissue blocks were cut into 5-m sections, placed on glass slides, and deparaffinized in sequential baths of xylene and 100% ethanol. After rehydration in PBS and treatment with 0.1% trypsin in PBS at 378C for 30 minutes, the tissue sections were blocked for endogenous peroxidase activity by incubation in 0.3% H 2 O 2 -absolute methanol for 30 minutes at room temperature. This pretreatment was followed by three washes in PBS, blocking for nonspecific staining with 2% normal rabbit serum and 5% BSA, and incubation in primary antibody solution (5 g/ mL purified rat anti-mouse CD31 [ Pharmingen, San Diego, CA ] in blocking solution ) for 2 hours at room temperature. Following three washes in PBS, tissue sections were covered with 50 L of biotinylated rabbit anti -rat IgG ( Vector Laboratories, Burlingame, CA ) at 5 g /mL dilutions in blocking solution. After a 60-minute incubation at room temperature, slides were washed again in PBS, processed for peroxidase staining using a commercial avidin-biotin complex method kit (Vectastain Elite ABC kit; Vector Laboratories ) and developed with 3,3 0 -diaminobenzidine tetrahydrochloride dihydrate ( DAB ) substrate ( metal enhanced DAB substrate kit; Pierce, Rockford, IL ). Subsequently, tissue sections were counterstained with Harris hematoxylin, washed in distilled water, dehydrated in sequential baths of ethanol and xylene, dried, mounted, and examined with a Zeiss Axiphot microscope. Photomicrographs were taken under the Zeiss Axiphot microscope with Kodak Ektar 25 film (ASA 100 ). In tissue -staining experiments, sections were also processed for hematoxylin and eosin staining to obtain descriptive histology.
Analysis of tissues for lacZ -GMEC targeting in vivo
After X -gal staining, various tissues from experimental and control animals were examined macroscopically with the help of an Olympus SO stereo (dissecting ) microscope fitted with a fiber optic illuminator. Lungs were first separated into individual lobes. Thereafter, X -gal -positive and -negative tumor nodules on the surface of the lobes were counted using the dissecting microscope before photograph. Survival analysis of B16 / F10 melanoma -bearing mice treated with i.v. injections of rhIL -2 -GMEC Survival studies were set up with different treatment groups of animals in an identical manner. Study endpoints were death or sacrifice of the animal when they appeared to be in distress, as evidenced by lethargy, difficulty in breathing, refusal to feed, or ruffled hair. Generally, untreated tumor-bearing animals started to exhibit some of these symptoms between 18 and 21 days after i.v. inoculation of B16 /F10 melanoma cells. All animal study protocols were approved by the Georgetown University Animal Care and Use Committee. Ethical guidelines for conducting research on laboratory animals were followed throughout these studies.
Statistical analysis
The Student's t test was used to compare the results between the control and experimental groups. A P value of less than .05 was considered to be statistically significant.
RESULTS
Targeting of pulmonary metastasis of breast tumors by lacZ transgene -expressing endothelial cells
In our previous study, we found that i.v. -administered GMEC migrated and preferentially integrated into blood vessels at sites of active angiogenesis that were induced by acidic fibroblast growth factor ( aFGF ) -secreting cells. 11 To determine whether macrometastases of breast tumors can sustain a level of angiogenesis that will enable migrating GMEC to survive, proliferate, and take part in neoangiogenesis at the local site, we administered a single i.v. injection of 10 5 lacZ -GMEC to mice with lung metastases of 4T1 mammary carcinoma. Two weeks following the administration of lacZ -GMEC to the tumor-bearing ani- OJEIFO, LEE, REZZA, ET AL: ENDOTHELIAL CELL-BASED GENE THERAPY mals, X -gal staining was observed at the sites of pulmonary metastases ( Fig 1C and Table 2 ). The X -gal -positive cells were seen in the immediate vicinity of the metastatic foci in the lungs. Small numbers of X -gal -stained cells were also detected at the subcutaneous site of the primary tumor. No X -gal -stained cell was seen in other tissues of these animals. Also, no X -gal -positive cell was seen in the lungs of untreated, tumor-bearing mice ( Fig 1A ) , or tumorbearing mice given neo-GMEC (endothelial cells transduced with the parent vector lacking the lacZ gene construct ) ( Fig 1B ) . Furthermore, we did not find X -gal -positive cells in lacZ -GMEC -treated, non -tumor-bearing mice (Table  2 ) , consistent with the hypothesis that tumor-associated angiogenesis promoted the survival of lacZ -GMEC at tumor sites. Interestingly, some lacZ gene -expressing cells were seen forming luminal structures containing blood elements, including leukocytes and erythrocytes ( Fig 2A ) , consistent with the incorporation of lacZ -GMEC within blood vessels.
Other lacZ gene -expressing cells were seen undergoing mitosis ( Fig 2B ) . The endothelial cell origin of the lacZ gene -expressing cells was confirmed using anti -PECAM-1 ( CD31 ) immunohistochemistry (Fig 2C ) .
Efficiency of GMEC targeting of tumor metastases in vivo
Once we had established that GMEC preferentially become incorporated within neo-vessels at metastatic sites, we investigated the efficiency of lacZ -GMEC tumor targeting. Two weeks after a single systemic administration of 10 5 lacZ -GMEC cells, we observed that about 32% of 4T1 lung metastases became X -gal positive (Table 3 ). The pattern of X -gal staining of the metastatic foci ranged from a few clusters of blue staining cells to diffuse blue staining of the tumors. Some tumors exhibited minimal or spotty staining ( Fig 1C ) , whereas others were diffusely X -gal positive ( Fig  1, C and D ) . The diffusely stained foci comprised about 10% of the individual metastases. Attempts to improve the targeting efficiency by increasing the dose of lacZ -GMEC up to 10 7 cells were unsuccessful. Whereas all the five mice treated with a single injection of 10 5 lacZ -GMEC had Xgal staining in and around their lung tumors, only three and two of the five mice in the groups that received 10 6 and 10 7 lacZ -GMEC, respectively, had detectable X -gal staining. Also, only focal punctate staining or a few X -gal -positive cell clusters were seen in these animals ( Table 2 ). The remaining animals in each group became ill and subsequently died following the administration of the larger doses of GMEC. These deaths may have occurred due to vascular occlusion in the lungs due to the large inoculum of GMEC.
To increase the targeting efficiency of lacZ -GMEC, we modified our protocol as follows: Once pulmonary metastases reached 1-2 mm in diameter, the primary tumor was removed to avoid continuous tumor seeding of the lungs. Three i.v. doses of 10 5 lacZ -GMEC were then administered to each animal, spaced 72 hours apart. The multiple lacZ -GMEC injections markedly increased the GMEC -targeting efficiency to multi focal tumor sites ( Table 4 and Figure 3 ) without any observable ill effects in the animals. Two weeks after the third i.v. dose of lacZ -GMEC, more than 94% of the individual lung metastases in tumor-bearing mice contained X -gal -positive cells ( Fig 3 and Table 4 ). Furthermore, the percentage of individual metastases with widespread lacZ -positive cells increased to more than 60% (Fig 3 ) . The specificity of the X -gal staining due to lacZ -GMEC targeting in these mice was again confirmed by the absence of X -gal -positive cells in the lungs of mice that received lacZ -GMEC alone, tumor cell alone, or tumor cells plus endothelial cells transduced with neo R gene -containing vector (neo-GMEC ) ( Table 4 ) .
Effects of rhIL -2 -GMEC on the growth of established pulmonary metastases of B16 / F10 melanoma
Having established that multiple i.v. administration of GMEC can effectively target tumor metastases with little or no toxicity in animals, we evaluated the therapeutic utility of this strategy in an experimental metastasis model of murine melanoma. We have previously shown that both macrovascular and microvascular endothelial cells expressing a human IL -2 transgene induce potent natural killer cell and cytotoxic T lymphocyte activation. 19 Also, rhIL -2 expression within and around tumors can elicit an antitumor effect. 22, 32, 33 Based on these observations, we predicted that the production of rhIL -2 by rhIL -2 -GMEC in the tumor microenvironment would result in the activation of immune effector cells while avoiding the toxicities that are associated with systemic cytokine administration. 32 To test this hypothesis, 1Â10
5 B16F10 melanoma cells were administered by tail vein injection to immunocompetent, syngeneic, C57Bl /6 mice. Seven to ten days following tail vein injection of these cells, at a time when many lung tumors became ''established'' ( i.e., tumors ranged from 1 to 2 mm in diameter ), we administered three i.v. injections of the rhIL -2 -GMEC via tail vein, spaced 72 hours apart. This multiple injection schedule was based on our earlier studies with the 4T1 mouse tumor model described above. The rhIL -2 produced by GMEC that were injected into animals ranged from 28 to 78 ng /10 6 cells per 24 hours ( 368-1000 IU / 10 6 cells per 24 hours ) ( Table 1 ) . As shown in Figure 4 , the systemic administration of rhIL -2 -GMEC caused a significant reduction in the tumor burden in the animals when compared to untreated or neo-GMEC -treated B16F10 tumor -bearing mice. Histological untreated ( controls, B ) . A total of 1Â10 5 B16F10 melanoma cells were injected into C57Bl / 6 mice ( eight or more per group ) via the tail vein. Seven to 10 days later, the animals received the first of three intravenous injections of 1Â10 5 rhIL -2 -GMEC or neo -GMEC spaced 3 days apart. The animals were then monitored for survival. The lungs of mice that died or were sacrificed when they became ill were removed and examined for the number and size of pulmonary metastases. To follow the rate of regression of lung metastases, other mice were sacrificed at periodic intervals after GMEC administration, their lungs removed and examined under a dissecting microscope. Note the presence of very few melanin pigment -containing metastatic foci in the lung from a treated mouse ( A ), whereas the lung from an untreated mouse ( B ) contains numerous metastatic foci. Magnification: Â31.
Cancer Gene Therapy, Vol 8, No 9, 2001 OJEIFO, LEE, REZZA, ET AL: ENDOTHELIAL CELL-BASED GENE THERAPY examinations of the lungs from untreated or neo -GMECtreated, tumor-bearing mice revealed numerous, large, melanin pigment -containing tumor foci. In contrast, the lungs of tumor-bearing mice treated with rhIL -2 -GMEC contained very few, small tumor foci (Fig 4 ) .
All control tumor-bearing animals, i.e., untreated tumorbearing mice or tumor-bearing mice treated with neo-GMEC, died by day 28. The median survival of untreated and neo -GMEC -treated tumor-bearing mice following the injection of B16F10 cells were 23 and 24 days, respectively. In contrast, B16F10 -bearing mice treated with rhIL -2-GMEC exhibited prolonged survival with a median of 42 days ( P <.02) ( Fig 5 ) . Most of the deaths of rhIL -2-GMEC -treated animals resulted from elective sacrifice to follow the rate of regression of the lung metastases and not due to illness. Thus, the reduction in tumor burdens was corroborated by an increase in survival indicating a marked antitumor effect by rhIL -2-GMEC treatment. Animals that received rhIL -2-GMEC alone without tumor cells remained alive and well (Fig 5 ) , indicating that rhIL -2 -GMEC administration was well tolerated. Furthermore, we did not find any significant statistical difference in the number of metastatic foci seen in the lungs of tumor-bearing mice with or without a GMEC implant, nor did we observe the appearance of tumors in normal mice that received multiple doses of rhIL -2 -GMEC alone, suggesting that systemic administration of the gene -modified endothelial cells did not promote tumor development in the animals.
DISCUSSION
Immune surveillance is compromised in patients with cancer and in tumor-bearing animals. 34 -38 A promising biological approach to the therapy of cancer metastases involves the use of cytokines to enhance the body's immune defenses against tumors. 32 IL -2, arguably the best characterized molecule used in this regard, will activate certain cells derived from the large granular lymphocyte population, causing those cells to exhibit antitumor cytolytic activity. 32, 33 IL -2 may also directly activate p56 trk , a protein associated with the IL-2 receptor -chain, thereby decreasing the susceptibility of CD8 + cells to inactivation by signals delivered by tumor cells. 38 Although a number of clinical trials have been carried out utilizing IL-2 or IL -2 -activated lymphocytes, this promising approach has been compromised by the severe dose -limiting toxicities associated with the systemic administration of IL -2. As a more effective method of achieving high intratumoral concentrations of cytokines and of minimizing their toxicity, various gene therapy approaches, including ( a) local delivery of cytokine genes to tumors by means of retroviral or adenoviral vectors, liposomes, or as naked DNA, 39 -41 (b) treatment using loco -regional delivery of gene-modified primary endothelial cells, 20, 22 or ( c) cancer vaccines consisting of tumor cells 32,42 -45 engineered to express IL -2 constitutively and/or other immune -activating genes in a paracrine manner, have been tested. Compared with systemically delivered cytokine proteins, these forms of immunotherapies have been shown to reduce tumorigenicity and metastasis in animal models without serious adverse effects. 20,22,39 -42 However, still lacking is a means of delivering therapeutic genes to metastatic sites throughout the body. A number of promising tumor or tumor vasculature targeting approaches are being studied, including the modification of the retroviral envelope glycoprotein, the use of antibodies, tumor / tissue -specific promoters, endothelial cell -specific receptors, and angiogenesis-specific peptides. 46 -54 Another novel form of targeted drug delivery system ( our model ) involves the systemic administration of primary endothelial cells that have been engineered to express therapeutic gene product( s) and that can target angiogenic sites. 11 The present study was designed to determine whether such a delivery method was feasible and effective for established metastases.
Because angiogenesis is an essential step in the growth and metastasis of tumors, 23, 24 we reasoned that the process of tumor angiogenesis might enable circulating GMEC to integrate into the developing capillary network of a tumor and subsequently express recombinant genes. 11 -13,15,16,20 To test this hypothesis, we initially administered a single dose of syngeneic, lacZ -expressing endothelial cells into animals bearing lung metastases. As predicted, i.v. -administered GMEC migrated into and preferentially accumulated at the sites of tumor metastases in the lungs. X -gal -positive cells were also seen at the subcutaneous sites of the primary tumor, suggesting that i.v. -injected GMEC can also migrate into tumor sites outside the lungs ( Table 2 ) . Apparently, in response to angiogenic factors elaborated by tumor cells at these places, GMEC were able to survive, proliferate, and become incorporated into the newly forming capillary networks (made up of both endogenous endothelial cells and GMEC ) ( Fig 2A -C ) . Furthermore, both vesselassociated and proliferating GMEC maintained endogenous ( PECAM -1 ) and recombinant ( lacZ ) gene expression at the tumor sites (Fig 2A -C ) . These results extend our earlier observations, 11 and suggest that angiogenic factors produced by tumors can sustain the survival of circulating GMEC, and their subsequent incorporation into the tumor vasculature.
In studies to determine the dose and schedule of lacZ -GMEC administration, we observed that over 90% of lung metastases were targeted after three i.v. injections of 10 5 GMEC, but not after a single dose of a larger inoculum ( Table 3 vs. Table 4 , Figure 2C vs. Figure 3 ) . One explanation for the poor tumor targeting following a single GMEC administration is the heterogenous angiogenic behavior of the individual tumor metastasis. That is, in certain instances the i.v. -injected lacZ -GMEC seeded growing tumors at an optimal time for incorporation and growth within the developing tumor vasculature. Other metastases, perhaps too small to sustain active angiogenesis, 24 may not promote GMEC incorporation and /or survival. In addition, following administration of a single small inoculum, GMEC are unlikely to target every tumor deposit present at the moment of injection. Another possibility is that bolus injection of large numbers of GMEC results in their accumulation in the lung microvasculature. This has been observed in our previous study of systemic GMEC administration, where most of the lacZ -expressing endothelial cells were retained by the lungs shortly after tail vein injection. 11 In the current study, we noted GMEC clumping and obstruction of small vessels following intravenous administration at high concentration ( 10 7 GMEC in 0.1 mL PBS, data not shown ). This probably accounts for the death of the majority of the animals treated with 10 7 lacZ -GMEC, as well as the low targeting efficiency of this dose in the survivors. Clearly, optimization of the schedule and concentration of GMEC administration ( e.g., slow continuous infusion ), as well as the route of administration ( e.g., intra-arterial ) will have to be explored in future studies.
Another factor affecting the efficiency of GMECtargeting of tumor metastases is the repetitive seeding of the bloodstream with tumor cells from the primary tumor or tumor cells dislodged from other sites. For these reasons, the kinetics of GMEC administration will determine, to a large extent, both targeting efficiency and extent of GMEC incorporation at a particular tumor deposit. This hypothesis is supported by the finding that the number of detectable pulmonary metastases decreased whereas the lacZ -GMECtargeting efficiency increased by 10% following complete removal of the primary tumor (data not shown ). The combination of complete removal of the primary tumor with multiple administration of lacZ -GMEC resulted in more than two -fold increase in tumor targeting.
The finding that i.v. -injected GMEC can preferentially accumulate at multiple tumor sites in the lungs and subcutaneous tissue led us to investigate the therapeutic utility of this novel approach. The results of our studies in the experimental metastasis model demonstrated that systemic administration of GMEC constitutively expressing a rhIL -2 transgene can mediate the regression of established tumor metastases and prolonged the survival of the tumor-bearing animals. Administration of GMEC with a control vector ( neo-GMEC ) did not elicit any reduction in tumor burden, suggesting that the tumor regression was mediated by rhIL -2 expression, presumably by stimulation of a local antitumor effector cells. 24, 32 Of interest, the administration of rhIL -2-secreting GMEC did not produce any observable toxicity, such as body weight loss or lethargy, as has frequently been reported in animals after systemic administration of IL-2 therapy. 32 In contrast, others have reported that i.v.-administered NIH3T3 16 or B16F10 melanoma cells 45 transduced to express IL -2 were unable to significantly reduce the rate of tumor growth. Because only a fraction of i.v. -administered cells would be expected to lodge at the site of tumors, the difference in these results may be related, in part, to the fact that the IL -2-GMEC, but not the IL -2 / NIH3T3 or lethally irradiated IL -2/B16F10 used in the other studies, proliferated in response to the angiogenic factors at the sites 11 ( Fig 2C ) , and, therefore, were able to attain the requisite number cells to produce levels of IL -2 that were sufficient to elicit an antitumor effect. Also, the capacity of the GMEC to readily participate in tumorassociated blood vessels formation (Fig 2, A and C ) , whereas NIH3T3 and B16F10 melanoma cells do not, may have permitted longer survival of the GMEC, and thus, expression of more IL -2 at the local tumor sites. Moreover, the strategic location of the GMEC at the interface of blood and tumor cells possibly accounted for enhanced activity of the expressed recombinant IL -2, thereby inducing a more effective antitumor immune response.
Nonendothelial cells such as lymphocytes, dendritic cells, and fibroblasts can be genetically modified, and are capable of expressing exogenous gene( s) at tumor sites. 55 -59 However, infusion of lymphocytes in patients has been associated with serious side effects, 32, 57 and fibroblasts have been reported to be incapable of maintaining long -term survival or expression of exogenous genes in vivo in the absence of a matrix scaffold. 55 The results of the present study demonstrate for the first time that targeted delivery of therapeutic gene -expressing endothelial cells to sites of tumor-associated angiogenesis is a feasible, efficient, safe, and potentially effective strategy to treat established tumor metastases in the lungs.
Our finding that fewer X -gal -positive cell clusters were seen at the subcutaneous tumor sites compared to the metastatic foci in the lungs suggests that the lung may be filtering out some of the circulating GMEC. Intra-arterial administration of GMEC using a catheter-based delivery system to by-pass the lung should eliminate this problem. The use of a catheter-based system would also permit selective infusion of specific organs with GMEC in the clinical setting.
Several reports have shown that hematopoietic stem / progenitor cells from human, dogs, mice, and rabbits can differentiate into cells expressing endothelial cell -specific makers in vitro and in vivo. 12,60 -65 In a number of these studies, Asahara et al, 12, 61 Takahashi et al, 62 Schatteman et al, 63 and Kalka et al 64 also demonstrated that endothelial cells derived from these precursor cells incorporate into neovasculature induced by wound healing, ischemia, corpus luteum, or tumorigenesis, while continuing to stably express foreign genes. Furthermore, when genetically modified to express a soluble, truncated form of the vascular endothelial growth factor receptor Flk -1 /KDR, endothelial precursor cells produced the recombinant Flk -1 protein that inhibited the migration of human umbilical vein endothelial cells in vitro and the growth of murine neuroblastoma cells in syngeneic mice in vivo. 65 These findings indicate that hematopoietic stem /progenitor cells may serve as sources of endothelial cells and that endothelial cells derived from these sources can be genetically engineered to deliver therapeutic molecules that would inhibit tumor growth as we have observed in our study. Therefore, in clinical application of our strategy, endothelial cells might be isolated from the patient's subcutaneous fat, bone marrow, or derived from stem /progenitor cells. We are currently investigating the in vivo distribution of endothelial cells from these sources, as well as their ability to target and abrogate tumors in organs where metastases frequently occur, including bone, brain, lungs, and liver.
In summary, our studies show that angiogenic factors elaborated by tumor metastases can mediate their specific targeting by intravenously administered GMEC in vivo. These results suggest that the administration of endothelial cells genetically modified to express therapeutic transgenes is a potentially safe and effective strategy for the treatment of metastatic disease. 
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